EuroBiotech—More articles of note


> Argenx capitalized on a more than 70% jump in its stock price by raising $231 million. The stock placement, which initially aimed to raise $150 million, followed shortly after the release of upbeat clinical trial data on two of argenx’s wholly owned candidates, ARGX-110 and ARGX-113. Release | More

> ADC Therapeutics posted updated data on ADCT-402 and ADCT-301. ADCT-402 achieved overall and complete response rates of 60% and 35%, respectively, in 68 patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The numbers for ADCT-301 came in at 77% and 44% in a trial of 27 patients with Hodgkin lymphoma. Release | More 

> A report looked at the rise of corporate venture capital in the U.K. Release 


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Shares in Cellectis rose following the publication of data on its Pfizer-partnered CAR-T candidate. The off-the-shelf therapy chalked up an 83% complete remission rate in a small study of patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia. Statement 

> Immunocore’s uveal melanoma candidate received Promising Innovative Medicine status. Release

> Cancer Research UK agreed to sponsor and fund a phase 1/2 trial of Scancell’s vaccine in combination with a checkpoint inhibitor in solid tumor patients. Statement

Suggested Articles

The World Health Organization has called out Big Pharma for its dearth of antibiotic innovation amid a growing threat of antimicrobial resistance.

The trial hit its primary endpoint by the time of an interim analysis, enabling Chi-Med to stop the study and start work on a filing for approval.

The anticipated fundraising haul will bankroll development of a pipeline of RAS programs up to the completion of IND-enabling studies.